Regeneron Pharmaceuticals Inc was Intellia Therapeutics’s largest revenue line in fiscal 2024, bringing in $32.40M of $55.90M (58%).
| Counterparty Name | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc | — | $22.40M | $32.40M | ||||||
| Regeneron | — | — | — | ||||||
| Avencell | — | $13.20M | $21.00M | ||||||
| Novartis | $300.00K | — | — | ||||||
| Sparing Vision | — | — | $2.50M | ||||||
| Total | $300.00K | $35.60M | $55.90M |
Intellia Therapeutics brought in $55.90M from its three revenue lines in fiscal 2024, the year ended December 31, 2024. Intellia Therapeutics regrouped these revenue lines after fiscal 2023, so the total does not compare directly with that year's $35.60M. Regeneron Pharmaceuticals Inc was the largest at $32.40M (58.0%), ahead of Avencell at $21.00M (37.6%) and Sparing Vision at $2.50M (4.5%).
Compared with fiscal 2023, Avencell grew 59.1% to $21.00M and Regeneron Pharmaceuticals Inc grew 44.6% to $32.40M.
Intellia Therapeutics began breaking out Avencell in fiscal 2023 and Sparing Vision in fiscal 2024. Intellia Therapeutics stopped reporting Novartis as a separate revenue line after fiscal 2021, when it brought in $300.00K.
Intellia Therapeutics (NTLA) reports its revenue by counterparty name. In fiscal 2024, Regeneron Pharmaceuticals Inc was its largest revenue line, bringing in $32.40M (58.0% of the total), followed by Avencell at $21.00M (37.6%).
Regeneron Pharmaceuticals Inc was Intellia Therapeutics' largest revenue line in fiscal 2024, bringing in $32.40M, or 58.0% of the $55.90M total across its three revenue lines.
Every figure comes from Intellia Therapeutics' annual financial filings, as reported. Each line keeps the name Intellia Therapeutics gives it, and years follow its fiscal calendar.
Intellia Therapeutics' revenue by counterparty name goes back to fiscal 2015, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.